Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Telitacicept · 2 trials · 2 indications
Change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.
The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale is scored on a 0 to 3 (0=normal, 3=severe disease) point scale. The total score is the sum of all individual item scores ranging from 0 to 24. Higher scores indicate more severe disability due to MG. A decrease from Baseline score indicates improvement.
| Arm | Type | Description |
|---|---|---|
| Telitacicept | EXPERIMENTAL | Telitacicept |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Telitacicept | BIOLOGICAL | Subcutaneous injection |
| Placebo | DRUG | Subcutaneous injection |
Inclusion Criteria: 1. Male or female aged 18 to 75 years of age (both inclusive) at screening 2. Participants must meet the 2016 American College of Rheumatology (ACR)/EULAR classification criteria for primary Sjogren's Syndrome at the time of screening. 3. ESSDAI ≥5 at screening (score calculated...
Telitacicept is an investigational monoclonal antibody being studied for the treatment of generalized myasthenia gravis and primary Sjogren's disease. It is currently in Phase 3 clinical development for both indications.
Telitacicept targets BLyS and APRIL, two proteins involved in B-cell survival and activity. By targeting these molecules, the drug aims to modulate the immune response in autoimmune conditions like generalized myasthenia gravis and primary Sjogren's disease.
Telitacicept is being developed by Vor Biopharma Inc., a company traded under the ticker symbol VOR. The company is conducting Phase 3 trials for the drug in generalized myasthenia gravis and primary Sjogren's disease.
Telitacicept is in Phase 3 clinical development. It is not yet approved by regulatory authorities and remains an investigational drug being studied for generalized myasthenia gravis and primary Sjogren's disease.
Telitacicept is being studied in two Phase 3 trials. NCT07404865 is a placebo-controlled study in primary Sjogren's disease with 250 participants in the United States. NCT06456580, known as UPSTREAM MG, is a placebo-controlled trial in generalized myasthenia gravis with 180 participants across multiple countries.
Yes, Telitacicept is being evaluated in randomized, double-blind, placebo-controlled Phase 3 trials. These trials are designed to assess the drug's efficacy and safety in patients with generalized myasthenia gravis and primary Sjogren's disease.